anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a biomarker-fused multitasking diabetic retinopathy detection algorithm, and relates to the problem of missed diagnosis caused by unobvious early DR (1-2 grade) characteristics in an automatic diagnosis technology of diabetic retinopathy (Diabetic retinopathy, DR). DR is a common diabetes complication, is a main factor of blindness of labor population, and has great influence on diabetes patients in China. Clinical experience shows that timely diagnosis and treatment can greatly reduce the risk of DR blindness, so that the method has very important practical significance for the regular DR screening of diabetics. But because medical resources in China are unevenly distributed, DR screening by using a computer-aided diagnosis technology is a very effective solution. Although the current DR automatic diagnosis technology based on deep learning has advanced to some extent, early DR (1-2 level) is not obvious, and the model is very easy to miss. To address this issue, a biomarker fused multiplexed diabetic retinopathy detection algorithm is presented herein. Experiments show that the method has the following advantages: (1) The change of early DR fundus blood vessel morphology is captured through calculating a biomarker, so that DR early diagnosis precision is improved (2) different characteristic weights are designed for different tasks by utilizing a voting mechanism, and the performance of a multi-task model is improved. The invention is applied to DR detection.
Soaps, liquid soaps and shampoos based on synthetic detergents contain a mycobacteriostat consisting of a compound having linked to a nitrogen atom of a biguanide either a halogen-containing aliphatic oxyphenyl group, the aliphatic oxy group of which has at least 2 carbon atoms, or an aliphatic oxyphenyl group in which the aliphatic substituent is a hydro-carbon substituent containing from 5 to 9 carbon atoms, or a salt of such a compound. Specified biguanides are those of the formula <FORM:1040733/C4-C5/1> where R is the aliphatic group which may be alkyl, alkenyl, cycloalkyl, or aralkyl.  The phenyl nucleus may be further substituted, e.g. with a halogen atom, nitro, amino, aryl, or aliphatic group.  A hydrogen atom in the biguanide residue may also be replaced by, for instance, an aliphatic or aromatic group. The salts may either be acid addition or quaternary ammonium salts.  The synthetic detergent materials in shampoos may be ionic, e.g. alkali metal salt of a sulphonated olive or castor oil, non-ionic, e.g. an ester or ether of a polyethylene glycol, or a mixture of both types.ALSO:Mycobacteriostatic compositions comprise a base that is pharmaceutically acceptable for external human use and as active ingredient less than 1% by wt. of the composition of a compound having linked to a nitrogen atom of a bignamide either a halogen-containing aliphatic oxyphenyl group, the aliphatic oxy group of which has at least 2 carbon atoms, or an aliphatic oxyphenyl group in which the aliphatic substituent is a hydrocarbon substituent containing from 5 to 9 carbon atoms, or a salt of such a compound.  Specified bignamides are those of the formula <FORM:1040733/A5-A6/1> where R is the aliphatic group, which may be alkyl, alkenyl, cycloalkyl, or aralkyl.  The phenyl nucleus may be further substituted e.g. it may contain a halogen atom, a nitro, amino, aryl, or aliphatic group (e.g. one of those specified above with reference to R).  A hydrogen atom in the bignamide residue may also be replaced by, for instance, an aliphatic or aromatic group. The salts may either be acid addition or quaternary ammonium salts.  The compositions may be in the form of ointments i.e. anhydrous solutions or dispersions of the active ingredient in a suitable base e.g. animal, vegetable, or mineral grease such as lard or petroleum jelly, oil e.g. olive, arachis, cottonseed or sesame oil, or wax e.g. beeswax.  The base may be an aqueous emulsion in which case the compositions contain either water-in-oil emulsifying agents such as lanolin or wool alcohols or oil-in-water emulsifying agents such as Emulsifying Wax B.P. Ear drops, medicated cosmetic and toilet preparations e.g. hand or body lotions, lipsticks, talcum powders, soaps, liquid soaps and shampoos based on synthetic detergents, may be other forms of the mycobacteriostatic compositions.
BACKGROUND: Insulin autoantibody syndrome (IAS), or Hirata disease, is caused by high concentrations of insulin autoantibodies, which result in spontaneous, mainly post-prandial, hypoglycemic episodes. We report a case of a previously healthy 67-year-old man presenting with recurrent fasting hypoglycemia culminating in a diagnosis of insulin autoimmune syndrome linked to omeprazole and probably spices, namely, coriander, and ginger.
CASE PRESENTATION: A previously healthy 67-year-old Sinhalese man presented with recurrent syncopal attacks for 3 months, which were found to be hypoglycemic episodes. He experienced mainly fasting hypoglycemic attacks, at a frequency gradually increasing to daily attacks. His cardiovascular, respiratory, abdominal, and neurologic examinations were normal. He was found to have insulin levels > 6000 mU/L and a post-polyethylene glycol insulin recovery of less than 9.5%. Contrast-enhanced computed tomography of the pancreas was normal. The diagnosis of insulin autoantibody syndrome was confirmed by testing for the insulin autoantibody level, yielding a level of > 300 U/mL. With regard to a possible trigger, he had a history of omeprazole intake for 2 weeks, 4 weeks prior to the onset of symptoms. He also consumed an herbal supplement containing coriander and ginger extracts daily for a period of 1 year, approximately 2 years prior to the onset of hypoglycemic attacks. He was commenced on prednisolone 30 mg daily, and hypoglycemic episodes responded dramatically, and thus he was tapered off corticosteroids.
CONCLUSION: Omeprazole-induced insulin autoantibody syndrome is likely in this patient; however, the known hypoglycemic effects of coriander and ginger make it worthwhile to consider a possible association with insulin autoantibody syndrome. In addition, this case report highlights the need to consider insulin autoantibody syndrome even in patients presenting with fasting hypoglycemic attacks.
The invention discloses a traditional Chinese medicine for treating aconuresis. The traditional Chinese medicine is characterized in that the traditional Chinese medicine is a decoction prepared from, by weight, 30 parts of radix rehmanniae preparata, 15 parts of tuber fleeceflower stem, 10 parts of cherokee rose fruits, 10 parts of fructus rubi, 15 parts of gorgon fruits, 10 parts of lotus stamen and 15 parts of herba ecliptae. The pure natural traditional Chinese medicine raw materials are selected, all the components meet the regulation of the drug law, the comprehensive effect of all the traditional Chinese medicine is utilized, the curative effect on aconuresis is achieved, no chemical sweetening agent is added, and the traditional Chinese medicine is innocuous and non-poisonous to the human body. The traditional Chinese medicine tastes slightly sweet, and is not bitter or wet and convenient to take. Cases are selected according to clinical observation in many years, a treatment course lasts six days, the medicine is taken twice every day, 50 ml of the medicine is taken every time, more than 3,000 patients are cured, the medicine is effective if all the symptoms completely disappear, and the total effective rate is 99%. The medicine can be widely used for clinically treating aconuresis.
To date 11 patients with Coffin-Siris syndrome type 7 (OMIM 618027) have been described since the first literature report. All reported patients carried de novo variants with presumed dominant negative effect, which localized in the PHD1/PHD2 domains of DPF2. Here we report on the first familial case of Coffin-Siris syndrome type 7. The index patient presented during the 1st year of life with failure to thrive and ectodermal anomalies. The genetic analysis using whole exome sequencing showed a likely pathogenic missense variant in the PHD1 region. The family analysis showed that the mother as well as the older brother of the index patient also carried the detected DPF2 variant in heterozygous state. The mother had a history of school difficulties but no history of failure to thrive and was overall mildly affected. The brother showed developmental delay with autistic features, ectodermal anomalies and overlapping morphologic features but did not have a history of growth failure problems. To our knowledge this is the first report of an inherited likely pathogenic variant in DPF2, underlining the variability of the associated phenotype as well as the importance of considering inherited DPF2 variants during the variant filtering strategy of whole exome data.
Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
The sequence of periods for each participant are assigned in random order. Each of the three crossover periods is 14 days of uninterrupted nightly dosing, with an initial lower-dose week of investigational product (IP) followed by a higher dose week (or placebo each week).
Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
Lower limb amputation is a serious and unfortunate outcome for many patients with vascular disease, especially those with diabetes. It results in significant decreases in all aspects of quality of life. The need for further surgery to revise the amputation to a more proximal level leads to increased potential for serious and life-threatening complications, as well as a decrease in patient morale. From surveys and background literature, it can be estimated that there are approximately 8600 vascular disease-related lower limb amputations in Canada each year. As the epidemic of diabetes continues to unfold and the mean age of the population increases, this number is expected to increase. The results of this study may significantly assist in the surgical and clinical care of this patient population by providing clinicians with a means to assess appropriate lower limb amputation levels.

Further, the modalities of transcutaneous measures may assist in guiding further intervention studies in higher risk patients to improve clinically important outcomes. This study will act in part as a feasibility trial for a randomized controlled trial assessing the efficacy of supplemental oxygen therapy, including hyperbaric oxygen therapy, as a therapeutic tool to increase rates of healing after lower limb amputation.
OBJECTIVE: Although the direct anterior approach can reduce muscle damage and ensure accurate prosthesis placement, the steep learning curve and increased risk of complications associated with DAA necessitate careful consideration. Therefore, we describe a technique for a novel percutaneously endoscopic-assisted total hip arthroplasty through mini bikini direct anterior approach (mDAA) and report the learning curve and initial outcomes.
METHODS: The first 125 THA performed by a single surgeon between September 2020 and February 2022 using the anterior approach were included, comprising the initial 41 cases of bikini DAA (bDAA) and the subsequent 84 cases of mDAA. Outcome measures included perioperative outcomes and postoperative complications. The cumulative sum analysis (CUSUM) was used to determine the learning curve of anterior approach THA for each patient's ORT. Multivariable analysis was performed to determine risk correlation.
RESULTS: A total of 125 anterior approach THA completed between 2020 and 2022 were identified. Among these, 41 were performed via bDAA and 84 via mDAA. No statistically significant differences were observed between the groups in terms of age, gender distribution, BMI or follow-up time. A significant reduction in ORT was noted, from 140 min for bDAA to 130 min for mDAA. Furthermore, there was a consistent decrease in LOI, LOS, and wound-healing problems. There was no statistically significant difference between groups with respect to Harris Hip Scores and other postoperative complications. The curve inflection points of the learning curve for the bDAA and mDAA group were located in the 22nd and 68th cases, respectively. The reduction of hemoglobin indicated a predicted increase in ORT.
CONCLUSIONS: In this study, ORT, LOI, LOS, and wound-healing problems decreased overall in mDAA group. After mastering the bDAA technique, approximately 27 mDAA cases are needed to acquire proficiency in this technique. Hence, mDAA is a valuable alternative for those seeking smaller incisions, resolving wound healing problems, and aiming for enhanced recovery after surgery.
A system is disclosed, for administering a therapeutic agent locally and to a depth within cardiac tissue. An elongate, flexible catheter contains a flexible electric conductor and supports at its distal end an implantable electrode incorporating a penetrating element, typically a fixation helix or a linear needle that penetrates cardiac tissue as the electrode is implanted. A therapeutic agent is delivered through the electrode, to the cardiac tissue surrounding the penetrating element. The electrode acts as a sensor, electrically coupled through the flexible conductor, and monitors an electrical condition of the surrounding cardiac tissue. A controller is coupled to the sensor and to a pump or reservoir containing the therapeutic agent, to control delivery of the agent responsive to the sensed electrical condition. The implanted electrode further can be used to deliver RF current to ablate the surrounding tissue. Several embodiments feature a distal reservoir adjacent the electrode, for effecting transient deliveries of the therapeutic agent in minute quantities or chronic delivery of growth factors. Another embodiment incorporates a bilumen catheter and a set of unidirectional valves, to facilitate changing therapeutic agents or purging the catheter of an agent after delivery.
BACKGROUND: As part of the UK government's obesity strategy, the Food (Promotion and Placement) (England) Regulations 2021 were implemented in October 2022 to restrict the prominent placement of products high in fat, sugar, or salt (HFSS) in most retail settings. Local authority (LA) officers have been tasked with enforcement of these regulations. This qualitative study examined the perspectives of LA officers including, trading standards, environmental health, and public health officers to understand enforcement approaches and requirements to optimise business compliance with the regulations.
METHODS: Semi-structured interviews were conducted via MS Teams with a purposive sample of LA officers across England. Data were analysed using inductive thematic analysis.
RESULTS: The 22 participants comprised 13 officers from Trading Standards, six from Environmental Health, and three from Public Health teams. The key messages include the following: (i) the regulations are complex and do not align with existing enforcement approaches, (ii) officers' professional background will result in variable enforcement practices, and (iii) compliance assessment is an arduous task. LAs are facing resource and workforce constraints and have to prioritise regulations addressing high health risks (e.g., allergens). Therefore, officers will mostly apply a light touch approach to enforcement, raising awareness and engaging with businesses rather than issuing notices. To develop a consistent enforcement approach across LAs, officers asked for (i) further leadership from central government in the form of funding, training, and tools to determine in-scope businesses and products, (ii) cross-departmental collaboration to raise the regulations' priority at local and regional levels, and (iii) greater consumer demand for healthier retail environments.
CONCLUSION: It is crucial to address both structural challenges such as resource allocation, workforce, and prioritisation issues as well as the inherent complexity of the regulations to strengthen enforcement efforts. Our findings highlight the necessity of supporting enforcement activities at national and regional government levels to avoid potential false conclusions about ineffectiveness of regulations.
The present invention relates to a biomarker useful in adoptive cell therapy. The biomarker in question is CD150, also known as SLAM or SLAMF 1. The applicant herein shows that expression of CD150 on tumor infiltrating lymphocyte infusion products correlates with the response rates observed in those patients. High CD150 expression can be seen in patients who continue to respond fully to treatment, while low expression can be seen in patients who do not respond to treatment. The present invention relates to the use of biomarkers to predict response rates or stratify patients for treatment. It also encompasses the general use of this receptor in adoptive cell therapy regimens, including but not limited to over-expressing the receptor in a T cell population or isolating cells expressing CD150 to increase efficacy.
In a randomized, double-blind, placebo-, exercise- and diet-controlled design, 60 subjects will participate in a 10-week study to determine the influence of selective protein timing on body composition, metabolic, and performance adaptations to resistance training. Diets will be individually standardized using the Cunningham equation adjusted for activity level to determine total maintenance calories. Carbohydrates, fats, and proteins will represent 50, 25, and 25 percent of the determined total calories. Diet counseling will occur weekly until stabilized and biweekly thereafter to ensure compliance with food and fluid intake. Protein will be distributed throughout the day as \>0.30g/kg bw/meal for breakfast, lunch, and dinner. Resistance training sessions will be supervised by research staff and occur 4 times per week and begin between 7 am and 5pm. Exercises will consist of single- and multi-joint exercises for all major muscle groups (legs, chest, back, shoulders, core, and arms), be performed for 3-5 sets of 1-20 repetitions with 1-5 minutes rest between sets, and each muscle group will undergo 72-96 hours rest between training sessions within the periodized program. Protein supplements. In the treatment group, the casein supplement (40g calcium caseinate dissolved in water) will be consumed as the last meal (\>2h following previous meal) before bed and the placebo (40g maltodextrin dissolved in water) either before resistance training, if training after 10am, or after resistance training, if before 10am. The control group will alternate consumption times of the casein supplement and placebo. The supplement (treatment group) or placebo (control group) will not be consumed within 3 hours of beginning or ending resistance training, nor will it be consumed within 3 hours of the first meal following waking. All groups will be provided with 0.30g/kg bw whey protein isolate immediately following training to facilitate recovery. Supplements will be consumed at a similar time of day on non-training days.
Prepn. of liposomes with cellular tropism and improved permeability for application of pharmaceuticals comprised attaching to the liposome membranes, covalently or by adsorption, enzymes; cell-specific immunoglobulins; specific factors corresp. to the target cells derived from cells or tissue extracts (or from membrane isolated from these) or their molecular subunits (A). (A) is obtd. by enzymatic degradation or controlled chemical decomposition of biological tissue using vapourised chemical reagents. Used for transporting pharmaceuticals to specific target cells, e.g. they can contain cytotoxic or cytostatic agenta and have coupled to the liposome membranes specific tumour antigens.
Dietary patterns and specific dietary components, in concert with the gut microbiota, can jointly shape susceptibility, resistance and therapeutic response to cancer. Which diet-microbial interactions contribute to or mitigate carcinogenesis and how they work are important questions in this growing field. Here we interpret studies of diet-microbial interactions to assess dietary determinants of intestinal colonization by opportunistic and oncogenic bacteria. We explore how diet-induced expansion of specific gut bacteria might drive colonic epithelial tumorigenesis or create immuno-permissive tumour milieus and introduce recent findings that provide insight into these processes. Additionally, we describe available preclinical models that are widely used to study diet, microbiome and cancer interactions. Given the rising clinical interest in dietary modulations in cancer treatment, we highlight promising clinical trials that describe the effects of different dietary alterations on the microbiome and cancer outcomes.
Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder characterized by hypoventilation due to impaired breathing control by the central nervous system and other symptoms of autonomic dysfunction. Mutations in paired-like homeobox 2 B (PHOX2B) are responsible for most cases of CCHS. Patients with CCHS have various phenotypes and severities, making the diagnosis difficult. This study aimed to present a comprehensive single-center experience of patients with CCHS, including key clinical features, treatment strategies, and outcomes. A retrospective chart review was performed for patients diagnosed with CCHS between January 2001 and July 2023 at Seoul National University Children's Hospital. Finally, we selected 24 patients and collected their demographic data, genotypes, ventilation methods, and clinical features related to autonomic dysfunction. The relationship between the clinical manifestations and genotypes was also examined. All patients used home ventilators, and tracheostomy was performed in 87.5% of patients. Fifteen (62.5%) patients had constipation and nine (37.5%) were diagnosed with Hirschsprung disease. Arrhythmia, endocrine dysfunction, and subclinical hypothyroidism were present in nine (37.5%), six patients (25.0%), and two patients (16.7%), respectively. A significant number of patients exhibited neurodevelopmental delays (19 patients, 79.2%). There was a correlation between the phenotype and genotype of PHOX2B in patients with CCHS. (r = 0.71, p < 0.001).   Conclusion: There was a positive correlation between paired-like homeobox 2 B mutations (especially the number of GCN repeats in the polyalanine repeat mutations sequence) and clinical manifestations. This study also demonstrated how initial treatment for hypoventilation affects neurodevelopmental outcomes in patients with CCHS. What is Known: • Congenital central hypoventilation syndrome is a rare genetic disorder characterized by hypoventilation and dysfunction of autonomic nervous system. • The disease-defining gene of CCHS is PHOX2B gene - most of the cases have heterozygous PARMs and the number of GCN triplets varies among the patients(20/24 - 20/33). What is New: • We have noted in the Korean patients with CCHS that there is a correlation between genotype (number of GCN repeats) and severity of phenotype. • National support for rare diseases allowed for a prompter diagnosis of patients with CCHS in Korean population.